Overview

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

Status:
Completed

Trial end date:
2000-08-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person recover from the side effects of chemotherapy. Combining chemotherapy with interferon alfa may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and interferon alfa followed by filgrastim in treating patients who have gastrointestinal tract cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Albert Einstein College of Medicine of Yeshiva University
Montefiore Medical Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Fluorouracil
Hydroxyurea
Interferon-alpha
Interferons
Lenograstim